Adaptive Biotechnologies Corporation (ADPT) — Financial statements
Income statement, balance sheet, and cash flow for Adaptive Biotechnologies Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 277↑54.8% | 179↑5.1% | 170↓8.1% | 185↑20.1% | 154 | |
| Cost of Revenue | 71↓1.0% | 72↓4.6% | 76↑30.5% | 58↑17.5% | 49 | |
| Gross Profit | 206↑92.4% | 107↑12.8% | 95↓25.6% | 127↑21.3% | 105 | |
| Operating Expenses | ||||||
| R&D Expenses | 94↓8.9% | 103↓15.7% | 122↓13.9% | 142↓0.4% | 142 | |
| General & Administrative Expenses | 73↓0.1% | 73↓13.3% | 84↓5.2% | 89↑18.8% | 75 | |
| Selling & Marketing Expenses | 95↑11.6% | 85↓4.3% | 89↓7.3% | 96↑0.1% | 95 | |
| SG&A Expenses | 167↑6.2% | 158↓8.7% | 173↓6.3% | 184↑8.3% | 170 | |
| Other Expenses | 2↓80.9% | 9↓67.2% | 27↑1496.7% | 2↑0.0% | 2 | |
| Operating Expenses | 263↓2.5% | 269↓16.3% | 322↓1.8% | 328↑4.3% | 314 | |
| Total Costs & Expenses | 334↓2.2% | 342↓14.0% | 397↑3.1% | 385↑6.1% | 363 | |
| Operating Results | ||||||
| Operating Income | -57↑64.9% | -163↑28.4% | -227↓13.4% | -200↑4.2% | -209 | |
| Depreciation & Amortization | 18↓7.4% | 19↓13.4% | 22↑6.3% | 21↑49.9% | 14 | |
| EBITDA | -30↑76.8% | -129↑32.0% | -189↓8.0% | -175↑9.4% | -193 | |
| EBIT | -48↑67.8% | -148↑30.0% | -212↓7.8% | -196↑5.4% | -207 | |
| Interest & Other Income | ||||||
| Net Interest Income | -2↓179.0% | 3↑70.7% | 2↑1051.1% | -0.18↓110.9% | 2 | |
| Interest Income | 9↓35.0% | 15↓6.4% | 16↑282.9% | 4↑143.2% | 2 | |
| Interest Expense | 12↑1.7% | 12↓16.1% | 14↑225.6% | 4 | 0.00 | |
| Non-Operating Income | -9↑35.0% | -15↑6.4% | -16↓282.9% | -4↓143.2% | -2 | |
| Other Income / Expenses | -2↓179.0% | 3↑70.7% | 2↑1051.1% | -0.18↓110.9% | 2 | |
| Income Before Tax | -59↑62.7% | -160↑29.2% | -225↓12.4% | -200↑3.3% | -207 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -59↑62.7% | -160↑29.2% | -225↓12.4% | -200↑3.3% | -207 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -59↑62.7% | -159↑29.2% | -225↓12.5% | -200↑3.4% | -207 | |
| Bottom-Line Net Income | -59↑62.7% | -159↑29.2% | -225↓12.5% | -200↑3.4% | -207 | |
| EPS (Basic) | -0.39↑63.9% | -1.08↑30.8% | -1.56↓56.0% | -1.00↑31.5% | -1.46 | |
| EPS (Diluted) | -0.39↑63.9% | -1.08↑30.8% | -1.56↓56.0% | -1.00↑31.5% | -1.46 | |
| Weighted Average Shares | 152↑3.1% | 147↑1.9% | 144↑1.3% | 143↑1.5% | 140 | |
| Weighted Average Diluted Shares | 152↑3.1% | 147↑1.9% | 144↑1.3% | 143↑1.5% | 140 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.